7th April 2020
A start-up that has taken advantage of several EIT Health programmes, HumanITcare is addressing the COVID-19 crisis by providing hospitals with free use of its remote patient monitoring platform.
The platform allows hospitals to administer care by remotely monitoring and treating patients with COVID-19 from home, hence reducing the risk of transmission. The tool can also show which areas of a city have been most affected by COVID 19.
HumanITcare’s platform consists of an App for both Android and IOS that automatically and digitally connects patients with healthcare professionals. By recording, processing, and displaying the patient’s detailed health data, the platform allows healthcare professionals to monitor the symptoms that patients experience and recommend care.
With location information provided by patients the platform will also allow health institutions to accurately see which areas of their cities have the most cases of COVID-19. The security of patient data is guaranteed with General Data Protection Regulation (GDPR)-compliant data encryption and anonymization.
HumanITcare has been a beneficiary of EIT Health support since 2017, when they joined the EIT Health Bootcamp Launch Lab programme. They participated in the EIT Health Headstart programme in 2018, the EIT Health E-Boat Bootcamp in 2019 and the EIT Health Bridgehead Europe programme in 2019.
The platform has already started working with hospitals in Spain to facilitate their tool for free. Further collaborations are welcomed at firstname.lastname@example.org.
Find out more here: https://humanitcare.com/platform-free-face-the-coronavirus-pandemic/
Philips ultrasound OK'd for COVID-19 lung, cardiac care
FDA approves use of firm's ultrasound portfolio to manage COVID-19-related complications
Backed by EIT Health Alumni, DAP aids care facilities
Digital Aid Project seeks to aid nursing homes, rehabilitation centres and mental health facilities
AstraZeneca to cooperate on Oxford's vaccine effort
Firm ready to facilitate distribution of Oxford University team's vaccination, which is already undergoing trials